Compare UBC Medical Indonesia Tbk. (LABS) vs Reksa Dana Danareksa ETF Indonesia Top 40 (XDIF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UBC Medical Indonesia Tbk. vs Reksa Dana Danareksa ETF Indonesia Top 40 — how do they compare? UBC Medical Indonesia Tbk. trades at Rp165 (market cap 635.95B, 843K 24h volume), while Reksa Dana Danareksa ETF Indonesia Top 40 trades at Rp419 (market cap 30.34B). The key difference: UBC Medical Indonesia Tbk. is far larger — about 21× Reksa Dana Danareksa ETF Indonesia Top 40's market cap. Which is the better fit depends on your goals.
| LABS | XDIF | |
|---|---|---|
Market Cap | 635.95B | 30.34B |
Volume | 843K | — |
Lot | 8.43K | — |
Turnover | 137.6M | — |
Average Price | 163.22 | — |
Value | 137.6M | — |
Indicative Equilibrium Price | 165 | — |
Indicative Equilibrium Volume | 246 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UBC Medical Indonesia Tbk.
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →
